Viatris tops forecasts as earnings and revenue beat expectations

Viatris Inc (NASDAQ:VTRS) reported fourth-quarter results that came in ahead of Wall Street forecasts, lifting its shares modestly in premarket trading.

The pharmaceutical group posted adjusted earnings per share of $0.57, exceeding analyst expectations of $0.54. Revenue reached $3.7 billion, topping the consensus estimate of $3.53 billion and marking a 5% increase compared with the same period last year.

Shares rose 1.4% ahead of the market open following the announcement.

On a reported basis, revenue grew 5% year over year, while operational growth — adjusted for divestitures — came in at 2%.

Sales of branded products performed strongly in Greater China and Emerging Markets, helping offset ongoing pressure in the generics business, where competition in North America and government pricing regulations in Japan weighed on performance.

For the full year, Viatris generated operating cash flow of $2.3 billion and returned more than $1 billion to shareholders during 2025.

“2025 was a year of strong execution across our global business, and we enter 2026 from a position of strength,” said Scott A. Smith, CEO of Viatris. “By realigning resources and prioritizing investments in the areas we believe will drive the greatest impact, we are positioning Viatris to deliver sustained revenue and earnings growth beginning in 2026.”

Looking ahead, the company forecast fiscal 2026 adjusted earnings per share of $2.33 to $2.47, with a midpoint of $2.40 slightly above analyst expectations of $2.39. Revenue is projected between $14.45 billion and $14.95 billion, with the midpoint of $14.7 billion exceeding the $14.37 billion consensus estimate.

Viatris also completed an enterprise-wide strategic review aimed at improving efficiency, targeting $650 million in total cost savings while reinvesting up to $250 million over the next three years.

As part of its restructuring program, the company expects to reduce its global workforce by up to 10%. Separately, a fire at its manufacturing facility in Nashik, India temporarily halted production in February, with operations anticipated to resume in April 2026.

Viatris stock price


Posted

in

by

Tags: